» Articles » PMID: 24076296

Regional Myocardial Sympathetic Denervation Predicts the Risk of Sudden Cardiac Arrest in Ischemic Cardiomyopathy

Abstract

Objectives: The PAREPET (Prediction of ARrhythmic Events with Positron Emission Tomography) study sought to test the hypothesis that quantifying inhomogeneity in myocardial sympathetic innervation could identify patients at highest risk for sudden cardiac arrest (SCA).

Background: Left ventricular ejection fraction (LVEF) is the only parameter identifying patients at risk of SCA who benefit from an implantable cardiac defibrillator (ICD).

Methods: We prospectively enrolled 204 subjects with ischemic cardiomyopathy (LVEF ≤35%) eligible for primary prevention ICDs. Positron emission tomography (PET) was used to quantify myocardial sympathetic denervation ((11)C-meta-hydroxyephedrine [(11)C-HED]), perfusion ((13)N-ammonia) and viability (insulin-stimulated (18)F-2-deoxyglucose). The primary endpoint was SCA defined as arrhythmic death or ICD discharge for ventricular fibrillation or ventricular tachycardia >240 beats/min.

Results: After 4.1 years follow-up, cause-specific SCA was 16.2%. Infarct volume (22 ± 7% vs. 19 ± 9% of left ventricle [LV]) and LVEF (24 ± 8% vs. 28 ± 9%) were not predictors of SCA. In contrast, patients developing SCA had greater amounts of sympathetic denervation (33 ± 10% vs. 26 ± 11% of LV; p = 0.001) reflecting viable, denervated myocardium. The lower tertiles of sympathetic denervation had SCA rates of 1.2%/year and 2.2%/year, whereas the highest tertile had a rate of 6.7%/year. Multivariate predictors of SCA were PET sympathetic denervation, left ventricular end-diastolic volume index, creatinine, and no angiotensin inhibition. With optimized cut-points, the absence of all 4 risk factors identified low risk (44% of cohort; SCA <1%/year); whereas ≥2 factors identified high risk (20% of cohort; SCA ∼12%/year).

Conclusions: In ischemic cardiomyopathy, sympathetic denervation assessed using (11)C-HED PET predicts cause-specific mortality from SCA independently of LVEF and infarct volume. This may provide an improved approach for the identification of patients most likely to benefit from an ICD. (Prediction of ARrhythmic Events With Positron Emission Tomography [PAREPET]; NCT01400334).

Citing Articles

Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes.

Zohora F, Nazari M, Sinusas A Curr Cardiol Rep. 2025; 27(1):61.

PMID: 40009333 DOI: 10.1007/s11886-025-02197-9.


Precision sampling of discrete sites identified during in-vivo functional testing in the mammalian heart.

Vermoortele D, Olianti C, Amoni M, Giardini F, De Buck S, Nagaraju C Commun Eng. 2024; 3(1):170.

PMID: 39543278 PMC: 11564904. DOI: 10.1038/s44172-024-00307-z.


Associations of the serum -6 PUFA concentrations with exercise-induced myocardial ischaemia in middle-aged and older men.

Esmaili H, Tajik B, Tuomainen T, Kurl S, Salonen J, Virtanen J Br J Nutr. 2024; 132(11):1522-1529.

PMID: 39523844 PMC: 11660311. DOI: 10.1017/S0007114524001971.


Prediction of major arrhythmic outcomes in ischaemic cardiomyopathy: value of hibernating myocardium in positron emission tomography/computed tomography.

Kovacs B, Gllareva V, Ruschitzka F, Duru F, Kaufmann P, Buechel R Eur Heart J Cardiovasc Imaging. 2024; 26(1):30-37.

PMID: 39213366 PMC: 11687117. DOI: 10.1093/ehjci/jeae232.


Sympathetic structural and electrophysiological remodeling in a rabbit model of reperfused myocardial infarction.

Guevara A, Smith C, Wang L, Caldwell J, Tapa S, Francis Stuart S Am J Physiol Heart Circ Physiol. 2024; 327(3):H631-H638.

PMID: 39028283 PMC: 11442023. DOI: 10.1152/ajpheart.00398.2024.


References
1.
Allman K, Wieland D, Muzik O, DeGrado T, Wolfe Jr E, Schwaiger M . Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol. 1993; 22(2):368-75. DOI: 10.1016/0735-1097(93)90039-4. View

2.
MOSS A, Hall W, Cannom D, Daubert J, Higgins S, Klein H . Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996; 335(26):1933-40. DOI: 10.1056/NEJM199612263352601. View

3.
de Haan S, Meijers T, Knaapen P, Beek A, van Rossum A, Allaart C . Scar size and characteristics assessed by CMR predict ventricular arrhythmias in ischaemic cardiomyopathy: comparison of previously validated models. Heart. 2011; 97(23):1951-6. DOI: 10.1136/heartjnl-2011-300060. View

4.
Bengel F, Schwaiger M . Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004; 11(5):603-16. DOI: 10.1016/j.nuclcard.2004.06.133. View

5.
Luisi Jr A, Suzuki G, DeKemp R, Haka M, Toorongian S, Canty Jr J . Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005; 46(8):1368-74. View